# Immunogenicity and Safety of MenACWY in Infants (6 & 12 Months)

> **NCT00310856** · PHASE2 · COMPLETED · sponsor: **Novartis Vaccines** · enrollment: 175 (actual)

## Conditions studied

- Meningococcal Meningitis

## Interventions

- **BIOLOGICAL:** MenACWY-CRM
- **BIOLOGICAL:** MenC-CRM
- **BIOLOGICAL:** DTaP-Hib-IPV
- **BIOLOGICAL:** PC7
- **BIOLOGICAL:** MMR
- **BIOLOGICAL:** Varicella

## Key facts

- **NCT ID:** NCT00310856
- **Lead sponsor:** Novartis Vaccines
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-06
- **Primary completion:** 2006-11
- **Final completion:** 2006-11
- **Target enrollment:** 175 (ACTUAL)
- **Last updated:** 2018-10-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00310856

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00310856, "Immunogenicity and Safety of MenACWY in Infants (6 & 12 Months)". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT00310856. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*